Stock Attack -- A Complete Analysis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Attack -- A Complete Analysis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Chris who started this subject	2/24/2001 5:20:18 PM
From: muscletwin	of 42787

PLMD and RETK. Worth a look: PLMD- Here is a recent excerpt from Morningstar.com article: "The company has growing earnings, free cash flow, and a balance sheet with no debt. Its historic revenue growth is 30% to 40%, yet its guidance for 2001 is conservative, 20+% growth. With a share price of $37 on February 12, PolyMedica has a P/E of 14 and a P/E-to-growth ratio of 0.70. I think this stock is valued right, is ripe to be discovered, and has room for an upside surprise."" Link to full article: biz.yahoo.com RETK- Heavy Institutional buying the past few months. Company has strong relations with IBM. Stock has held up much better than other B2B companies. No debt. Company continues to sign new customers. Last quarter reported strong growth software licensing growth, which is high margin revenue. Have clients such as Walmart, Barnes & Noble, Best Buy, Kohl's and A&P. Just to name a few.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next